The combination of a 95% bullish consensus, strong insider buying, heavy institutional accumulation, and upward EPS revisions makes IMNM a high-conviction long. The elevated short interest (72.4%) adds squeeze potential. Traders should consider adding to positions on any pullback, with a target near the $35-$36 consensus.
Price Chart
Executive Summary
Barclays initiated coverage on Immunome Inc. (IMNM) at Overweight with a $36 price target, implying 66% upside from the current $21.66. The call aligns with an overwhelmingly bullish consensus — 95% of 20 analysts rate the stock Buy or Strong Buy, with only one Hold. The mean price target of $35.23 is nearly identical to Barclays' $36, placing the firm in line with the Street. Barclays carries a 54% accuracy rate on 6,762 calls with a +3.9% average return, a solid but not elite track record. EPS revisions have been strongly positive over the past 30 days — 9 upward revisions vs. 1 downward — signaling improving fundamentals. Insider activity shows a notable buy from director Clay B. Siegall ($500K) on March 27 and a $103K buy from Jean Jacques Bienaime on May 15, both bullish signals that converge with the analyst upgrade. Institutional buying is also heavy, with FMR LLC adding 26.8% and Bank of America doubling its position. The bottom line: Barclays' initiation is a consensus-aligned call from a mid-tier firm, but strong insider buying and institutional accumulation add conviction to the bullish thesis.
Impact Score
Consensus & Targets
Of 20 analysts covering IMNM, 6 rate it Strong Buy, 13 Buy, 1 Hold, 0 Sell, and 0 Strong Sell — a 95% Buy/Strong Buy ratio. The consensus is overwhelmingly bullish, with only a single Hold dissenter. No Sell ratings exist.
Current price: $21.66. Mean target: $35.23 (63% upside). Median: $35.00. High: $40.00 (HC Wainwright). Low: $30.00. Barclays' $36 target sits slightly above the mean and median, in the upper half of the range but not the highest.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-05-28 | Barclays | initiate | Overweight | $36.00 |
| 2026-05-15 | Leerink Partners | maintain | Outperform | $33.00 |
| 2026-05-13 | HC Wainwright & Co. | reiterate | Buy | $40.00 |
| 2026-03-04 | Craig-Hallum | maintain | Buy | — |
| 2026-03-04 | Stephens & Co. | maintain | Overweight | — |
| 2026-02-12 | HC Wainwright & Co. | initiate | Buy | $40.00 |
| 2026-01-15 | Wedbush | reiterate | Outperform | $31.00 |
| 2025-12-16 | Lake Street | maintain | Buy | $32.00 |
| 2025-12-16 | Evercore ISI Group | maintain | Outperform | $40.00 |
| 2025-12-16 | Guggenheim | maintain | Buy | $35.00 |
Over the past 30 days, 9 EPS revisions up and 1 down for the current fiscal year, and 9 up and 0 down for the current quarter — a strong upward revision trend. Analyst actions show 1 upgrade (Barclays initiation) and 0 downgrades in the past 30 days. The momentum is clearly bullish.
Firm Track Record — Barclays
Barclays accuracy: 54% on 6762 calls | avg return: 3.9%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 7 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| JP Morgan | 100% | 2/2 | 32.2% | top tier |
| Stephens & Co. | 67% | 2/3 | 3.3% | top tier |
| Evercore ISI Group | 50% | 1/2 | 33.3% | below average |
| Lake Street | 50% | 1/2 | 7.7% | below average |
| Guggenheim | 50% | 2/4 | 11.8% | below average |
| Piper Sandler | 33% | 1/3 | -6.5% | below average |
| Wedbush | 25% | 1/4 | -19% | below average |
Barclays has a 54% accuracy rate on 6,762 scored calls with a +3.9% average return — a solid, average-performing firm. Among firms covering IMNM, top-tier performers include JP Morgan (100% on 2 calls, +32.2% avg return) and Stephens & Co. (67% on 3 calls, +3.3%). Weakest is Wedbush (25% on 4 calls, -19% avg return). Barclays' initiation is in line with its typical performance.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0y | $-2.14 | $-2.45 — $-1.84 | $2.5M | ↑9 ↓0 |
| 0q | $-0.51 | $-0.64 — $-0.41 | $166.7K | ↑9 ↓0 |
| +1q | $-0.56 | $-0.73 — $-0.48 | $166.7K | ↑9 ↓0 |
| +1y | $-2.00 | $-2.58 — $-1.25 | $81.6M | ↑6 ↓0 |
Cross-Platform Signals
Insider trades show two notable buys: director Clay B. Siegall bought $500K on March 27 and Jean Jacques Bienaime bought $103K on May 15 — both bullish signals that converge with the analyst upgrade. Insider sales (Higgins $204K, Rosett $1.4M, Wagenheim $582K) are present but are not clustered and may be liquidity-driven. Institutional activity is heavily bullish: FMR LLC added 26.8% ($355M position), Bank of America doubled (+120%), Wells Fargo doubled (+110%). One exit by Renaissance Technologies is a minor divergence. Short interest is elevated at 72.4% of float, which could fuel a squeeze if positive catalysts emerge. The convergence of insider buys, institutional accumulation, and analyst bullishness is a strong signal.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 1d ago | ANALYST-UPGRADE | $21.58 awaiting T+5 | awaiting T+5 | — | $20.97 (−2.85%) |
Sep 21, 2026 11d ago | ANALYST-UPGRADE | $25.07 $21.68 | ▼ −13.52% | ▼ −13.24% | $20.97 (−16.37%) |
Aug 12, 2026 7w ago | Insider Cluster | $26.42 $28.08 | ▲ +6.28% | ▲ +8.25% | $20.97 (−20.65%) |
Aug 10, 2026 7w ago | Insider Cluster | $26.25 $27.56 | ▲ +4.99% | ▲ +5.39% | $20.97 (−20.13%) |
Jul 9, 2026 12w ago | Insider Cluster | $23.35 $22.20 | ▼ −4.93% | ▼ −4.36% | $20.97 (−10.21%) |
Jul 7, 2026 12w ago | Insider Cluster | $24.01 $22.59 | ▼ −5.91% | ▼ −6.78% | $20.97 (−12.68%) |
Jul 7, 2026 12w ago | Insider Cluster | $24.01 $22.59 | ▼ −5.91% | ▼ −6.78% | $20.97 (−12.68%) |
Jul 3, 2026 13w ago | Insider Cluster | $23.61 $24.17 | ▼ −2.37% | ▼ −1.44% | $20.97 (+11.20%) |
May 28, 2026 18w ago | ANALYST-UPGRADE | $22.54 $19.81 | ▼ −12.11% | ▼ −12.06% | $20.97 (−6.99%) |
May 12, 2026 20w ago | 8-K | $22.20 $19.66 | ▼ −11.44% | ▼ −10.28% | $20.97 (−5.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access